cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Marinus Pharmaceuticals Inc
2 own
17 watching
Current Price
$6.71
$0.22
(3.39%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
249.59M
52-Week High
52-Week High
12.37
52-Week Low
52-Week Low
3.465
Average Volume
Average Volume
1.05M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization249.59M
icon52-Week High12.37
icon52-Week Low3.465
iconAverage Volume1.05M
iconDividend Yield--
iconP/E Ratio--
What does the Marinus Pharmaceuticals Inc do?
Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY, an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company s ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, tuberous sclerosis complex, depressive disorders, and Lennox-Gestaut Syndrome. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation. The company was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.
Read More
How much money does Marinus Pharmaceuticals Inc make?
News & Events about Marinus Pharmaceuticals Inc.
Business Wire
3 months ago
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the pricing of its underwritten public offering of 10,526,316 shares of its common stock at a public offering price of $4.75 per...
Business Wire
3 months ago
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it has entered into a revenue interest financing agreement with Sagard Healthcare Partners for a total of $32.5 million...
Business Wire
6 months ago
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the grant of inducement awards to seven new employees. The Compensation Committee of the Board of Directors of Marinus approved...
Business Wire
8 months ago
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that management will participate in the following investor and medical conferences in May and June: Citi Biotech Virtual...
Frequently Asked Questions
Frequently Asked Questions
What is Marinus Pharmaceuticals Inc share price today?
plus_minus_icon
Can Indians buy Marinus Pharmaceuticals Inc shares?
plus_minus_icon
How can I buy Marinus Pharmaceuticals Inc shares from India?
plus_minus_icon
Can Fractional shares of Marinus Pharmaceuticals Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Marinus Pharmaceuticals Inc stocks?
plus_minus_icon
What is today’s traded volume of Marinus Pharmaceuticals Inc?
plus_minus_icon
What is today’s market capitalisation of Marinus Pharmaceuticals Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Marinus Pharmaceuticals Inc?
plus_minus_icon
What percentage is Marinus Pharmaceuticals Inc down from its 52-Week High?
plus_minus_icon
What percentage is Marinus Pharmaceuticals Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$6.71
$0.22
(3.39%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc.
$65.95
$0.50 (0.76 %)
PROQR THERAPEUTICS NV
PROQR THERAPEUTICS NV
$3.00
$0.10 (3.45 %)
Arbutus Biopharma Corporation
Arbutus Biopharma Corporation
$2.95
$0.05 (1.72 %)
Paratek Pharmaceuticals, Inc.
Paratek Pharmaceuticals, Inc.
$2.12
$-0.03 (-1.40 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc.
$65.95
$0.50 (0.76 %)
PROQR THERAPEUTICS NV
PROQR THERAPEUTICS NV
$3.00
$0.10 (3.45 %)
Arbutus Biopharma Corporation
Arbutus Biopharma Corporation
$2.95
$0.05 (1.72 %)
Paratek Pharmaceuticals, Inc.
Paratek Pharmaceuticals, Inc.
$2.12
$-0.03 (-1.40 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00